Third Rock Ventures V, L.P.

Insider profile

Performance

Overall performance
3.2

Performance over holding periods
3.2
30 days 90 days 120 days
Average return 6% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Third Rock Ventures V, L.P.'s trades of Rapport Therapeutics Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2026-05-28 2026-05-26 PlS Planned sale
37,434 +3.1%
132.56
US$2,527,847
37,434 +3.1% 132.56 US$2,527,847
2026-05-27 2026-05-26 PrS Proposed sale
74,555
192.88
US$2,812,387
74,555 192.88 US$2,812,387
2026-05-13 2026-05-11 PlS Planned sale
21,561 -25.3%
456.79
US$3,268,804
21,561 -25.3% 456.79 US$3,268,804
2026-05-11 2026-05-11 PrS Proposed sale
133,618
40.25
US$5,378,124
133,618 40.25 US$5,378,124
2026-05-11 2026-05-08 PlS Planned sale
5,018 -0.1%
40.31
US$202,256
5,018 -0.1% 40.31 US$202,256
2026-05-08 2026-05-08 PrS Proposed sale
5,018
40.31
US$202,254
5,018 40.31 US$202,254
2026-05-08 2026-05-08 PrS Proposed sale
5,018
40.31
US$202,254
5,018 40.31 US$202,254
2026-05-11 2026-05-07 PlS Planned sale
271,495 -4.0%
40.12
US$10,892,651
271,495 -4.0% 40.12 US$10,892,651
2026-05-07 2026-05-07 PrS Proposed sale
271,495
40.12
US$10,892,705
271,495 40.12 US$10,892,705
2026-04-21 2026-04-17 PlS Planned sale
426,005 -6.0%
40.32
US$17,175,244
426,005 -6.0% 40.32 US$17,175,244
2026-04-17 2026-04-17 PrS Proposed sale
426,005
40.32
US$17,175,116
426,005 40.32 US$17,175,116
2024-10-28 2024-10-28 B Purchase
279,500 +9.7%
18.00
US$5,031,000
279,500 +9.7% 18.00 US$5,031,000
2024-10-28 2024-10-28 B Purchase
370,500 +6.3%
18.00
US$6,669,000
370,500 +6.3% 18.00 US$6,669,000
2023-11-14 2023-11-14 B Purchase
1,333,333 +281.4%
15.00
US$19,999,995
1,333,333 +281.4% 15.00 US$19,999,995